Akademik Məlumat İdarəetmə Sistemi
Pharmacy Practice, vol.23, no.1, 2025 (ESCI)
Background: The specificity of CHF is a high rate of recurrent hospitalizations for acute decompensation of heart failure (ADHF). One of the important aspects of monitoring the patient’s condition is monitoring the volemic status-identifying and determining the degree of stagnation for the timely optimization of the treatment regimen in order to prevent re-hospitalization. In this regard, of great interest is a new technology for non-invasive measurement of fluid levels in the lungs, implemented in a medical product under the ReDS brand (manufactured by Sensible Medical, Israel). ReDS™ (from remote dielectric sensing) technology is a quantitative, non-invasive method for measuring total lung fluid volume in patients with fluid drainage problems, including those with heart failure. It may be implemented at inpatient, outpatient and pharmacy levels. The results of the assessment showed that at a given level of implementation of ReDS technology, the number of readmissions at the inpatient level will decrease from 375 703 to 252 208 per year, and at the outpatient level from 375 703 to 252 208 per year. This corresponds to a decrease in the annual cost of recurrent hospitalizations from 24.93 billion rubles. respectively to 20.96 (by 15.9%) billion rubles. and 19.70 billion rubles. (21.0% reduction, including additional costs for patient visits to measure for ReDS). At the same time, one-time costs for the purchase of 1 234 units of a ReDS medical device for an outpatient level or 1 129 units of a ReDS medical device for an inpatient level amount to 12.06 billion rubles or 11.04 billion rubles, respectively. The results of the “budget impact” analysis (taking into account the discount factor of 3.5%) of the introduction of ReDS technology at the outpatient level demonstrate that over 7 years it provides cost savings in the amount of 20.33 billion rubles, up to 45.92 billion rubles, and at the stationary level – 13.61 billion rubles.